Cannabix Technologies Inc.·Healthcare

VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing devices for workplace safety and law enforcement, is pleased to announce the commercial delivery of its Marijuana Breath Test (“MBT”) products to a leading industrial manufacturing company with operations in the state of Virginia. The delivery was completed through an authorized reseller. The announcement highlights diverse industries that are adopting the Company's non-invasive breath-based testing products to support workplace safety programs.

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing devices for workplace safety and law enforcement, is pleased to announce the first commercial sales of its Marijuana Breath Test (“MBT”) products into the construction industry. The products were sold to a major construction company located in the Pacific Northwest through an authorized reseller. The client—a large regional contractor engaged in industrial, civil, and commercial construction—sought a next-generation solution to strengthen workplace safety protocols by accurately assessing recent cannabis use among its workforce.

VANCOUVER, British Columbia, March 16, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) is pleased to announce the commencement of its commercial phased rollout of the Marijuana Breath Test (“MBT”) system. This phase includes the delivery of MBT units to select commercial customers across multiple industries, followed by a planned scale-up in production.

MOGADORE, Ohio and VANCOUVER, BC, March 3, 2026 /PRNewswire/ -- Omega Laboratories, Inc. and Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) proudly announce the peer‑reviewed publication of a groundbreaking study published by Oxford University Press in the prestigious Journal of Analytical Toxicology titled: "Simultaneous Analysis of Δ9‑THC, Δ8‑THC, CBD, and CBN in Breath Aerosols Collected Using Cannabix Technologies Breath Collection Unit." This marks a major milestone in the advancement of marijuana breath testing technology globally.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES ORFOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (the “Company” or “Cannabix”) announces it has closed its previously announced non-brokered private placement financing (the "Offering") with the issuance of 1,400,000 units of the Company (the “Units”) at an issue price of CDN$0.50 per Unit for aggregate gross proceeds of CDN$700,000. Each Unit consists of one common share in the capital of the Company (a “Share”) and one non-transferable common share purchase warrant (a “Warrant”).

Shares of Cannabix Technologies Inc. (OTCMKTS:BLOZF - Get Free Report) dropped 3.6% during trading on Wednesday. The stock traded as low as $0.3914 and last traded at $0.4035. Approximately 134,463 shares changed hands during mid-day trading, an increase of 29% from the average daily volume of 104,623 shares. The stock had previously closed at
Cannabix Technologies Inc., a technology company, develops marijuana breathalyzer for employers, law enforcement, governments, and public in North America. It develops tetrahydrocannabinol breath analyzers, a point of care breath testing tool for the rapid detection of recent cannabis use, as well as breath collection units. The company was formerly known as West Point Resources Inc. and changed its name to Cannabix Technologies Inc. in August 2014. Cannabix Technologies Inc. was incorporated in 2011 and is based in Burnaby, Canada.